Hester Biosciences Nepal plant at Nala Ugrachandi

Hester Biosciences Nepal, a joint venture company of Golchha Organisation and Hester Biosciences Limited India, a leading health care company has launched a new plant at Nala Ugrachandi in Kavre district. Hester Biosciences Nepal is a private sector unit which will be manufacturing animal vaccines. On February 13, Prime Minister K.P. Sharma Oli inaugurated Hester Biosciences Nepal’s new plant.

On the occasion, Prime Minister Oli said, “Nepal is a country where most people’s source of income is livestock farming. The operation of Hester Biosciences in Nala will facilitate farmers in livestock production which will contribute towards the economy growth, increase in household income and urbanisation. More than 90% of the vaccines from Hester Biosciences are exported. With this plant in Nepal, there will be ample number of jobs created and revenue generation as well.”

Minister for Finance Yubaraj Khatiwada expressed that such ventures that are export oriented will help the economy in a sustainable way and there is a need to prioritise such type of industries. “The multi dimension of Hester Biosciences to serve Nepal’s market as well as the international market is praise worthy,” added Khatiwada.

Speaking about the company, Rajiv Gandhi, CEO and Managing Director of Hester Biosciences Nepal said, “Emerging animal diseases have been a threat which needs to be addressed. We have advanced technology to manufacture vaccines and cure animals. We believe our new plant with quality products and affordable price will help reduce the problems faced by the farmers in livestock production. We have always strived to control and maintain quality of our products. We definitely will do the same and aim for better in Nepal.”

Shekhar Golchha, Executive Director of Golchha Organisation highlighted that government should give high priority for promotion of animal health care companies in Nepal since the demand of livestock production has been increasing.

Hester has a state-of-the-art manufacturing facility for products ranging from poultry vaccines to large animal vaccines. The facility has been built according to GMP standards and norms, with an annual capacity to manufacture 1.24 billion doses of live and inactivated vaccines. Currently the company has got 20 licensed vaccines and 27 vaccines are under licensing. The company has also exported two crore doses of animal vaccine.

Share This Post

B360

Business 360 is a magazine that delivers on quality business news content, profiles of entrepreneurs and leaders, features on issues that matter, articles that assess and analyze policy and delivery mechanisms in the world of trade and commerce

Related Post